Hope WW - Search Results

1

Tissue penetration of antifungal agents.

Felton T, Troke PF, Hope WW. Felton T, et al. Among authors: hope ww. Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. Clin Microbiol Rev. 2014. PMID: 24396137 Free PMC article. Review.

2

Therapeutic drug monitoring for triazoles.

Hope WW, Billaud EM, Lestner J, Denning DW. Hope WW, et al. Curr Opin Infect Dis. 2008 Dec;21(6):580-6. doi: 10.1097/QCO.0b013e3283184611. Curr Opin Infect Dis. 2008. PMID: 18978525 Review.

3

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Warn PA, et al. Among authors: hope ww. Antimicrob Agents Chemother. 2009 Aug;53(8):3453-61. doi: 10.1128/AAC.01601-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451288 Free PMC article.

4

Therapy for fungal diseases: opportunities and priorities.

Denning DW, Hope WW. Denning DW, et al. Among authors: hope ww. Trends Microbiol. 2010 May;18(5):195-204. doi: 10.1016/j.tim.2010.02.004. Epub 2010 Mar 6. Trends Microbiol. 2010. PMID: 20207544 Review.

5

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. Hope WW, et al. Antimicrob Agents Chemother. 2010 Nov;54(11):4879-86. doi: 10.1128/AAC.00673-10. Epub 2010 Aug 16. Antimicrob Agents Chemother. 2010. PMID: 20713673 Free PMC article.

6

Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.

Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Felton TW, et al. Among authors: hope ww. Clin Infect Dis. 2010 Dec 15;51(12):1383-91. doi: 10.1086/657306. Epub 2010 Nov 5. Clin Infect Dis. 2010. PMID: 21054179

7

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. Howard SJ, et al. Among authors: hope ww. J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28. J Infect Dis. 2011. PMID: 21357943 Free PMC article.

8

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Troke PF, Hockey HP, Hope WW. Troke PF, et al. Among authors: hope ww. Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18. Antimicrob Agents Chemother. 2011. PMID: 21768513 Free PMC article.

9

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW. Howard SJ, et al. Among authors: hope ww. Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7. doi: 10.1128/AAC.00621-11. Epub 2011 Aug 1. Antimicrob Agents Chemother. 2011. PMID: 21807969 Free PMC article.

10

Population pharmacokinetics of voriconazole in adults.

Hope WW. Hope WW. Antimicrob Agents Chemother. 2012 Jan;56(1):526-31. doi: 10.1128/AAC.00702-11. Epub 2011 Nov 7. Antimicrob Agents Chemother. 2012. PMID: 22064545 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

279 results

Search Page

Filters